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The use of small stents to delay 
surgical intervention in very 
young children with critical 
congenital heart disease
These are major causes of early morbidity and mortality. Poor 
clinical condition at the time of surgery also plays a role in exac-
erbating the outcome as this may increase the risk of shunt 
occlusion.(7,8) Prostaglandin E1, as a continuous intravenous 
infusion to maintain ductus arteriosus patency, is often used in 
resource limited settings where waiting lists for surgery are 
lengthy. This may be at the expense of well known reported 
side effects such as apnea requiring prolonged ventilation, 
convulsions, necrotising enterocolitis and fever.(2,9)
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CRITICAL CHD – 
STENT TO DELAY 
SURGERY
INTRODUCTION
Critical obstructive congenital heart disease in very young 
children is often lethal and may require immediate life-saving 
interventions. Primary corrective surgery remains the treatment 
of choice for these lesions (e.g. coarctation of the aorta [COA], 
right ventricular outflow tract [RVOT] obstruction). Overall 
surgical mortality in this group of seriously ill patients varies 
between 10% and 40% and pre-operative cardiorespiratory 
status and associated lesions influence outcomes with regards 
to predictability and consistency.(1-4)
In cases where it is not possible to proceed to immediate 
corrective surgery, alternative treatment options may be con-
sidered. These situations include: low or very low birth weight 
newborns, severe infectious risk, haemodynamic instability, 
technical and system factors.(2) Alternative treatment options 
include palliative surgery, prolonged prostaglandin administra-
tion, balloon angioplasty and stent implantation.
In units where primary repair is not possible or an option, 
placement of a systemic-to-pulmonary artery shunt (e.g. Blalock 
Taussig and Sano shunt) are frequently used in the management 
of lesions with compromised pulmonary blood flow (e.g. severe 
tetralogy of Fallot and critical RVOT obstruction). However, 
this procedure has been associated with numerous compli-
cations such as differential pulmonary artery flow and distortion, 
pulmonary over circulation, kinking, stenosis, thrombosis, chylo-
thorax and phrenic nerve palsy.(1,2,5-7)
Introduction: Surgery in very young children with critical 
obstructive congenital heart disease has a high mor-
bidity and mortality. The aim of this study was to deter-
mine whether the use of small stents is feasible and if it 
could delay surgery. 
Materials and methods: Nineteen children were included 
in a retrospective review spanning 7 years. Patients were 
included in circumstances where surgery needed to be 
delayed and the use of a small stent could alleviate the 
underlying obstruction. 
Results: All attempts at stenting were successful (100%). 
Indications were diverse and included: aortic obstruc-
tion (n=9), right ventricular outfl ow tract obstruction 
(n=3), systemic-to-pulmonary artery shunt occlusion 
(n=5), infradiaphragmatic pulmonary vein obstruction 
(n=1) and salvage of a discontinuous left pulmonary 
artery (n=1). Reasons patients were not fi t for surgical 
intervention included: low weight (n=4), poor general 
clinical condition (n=12), surgical technical diffi culty 
(n=2) and unavailability of a critical care bed (n=1). 
Median age and weight at procedure was 4.6 months 
(range: 0.1 - 18.3) and 4.5kg (range: 1.7 - 9.5), respectively. 
Pressure gradients and saturations showed signifi cant 
improvement post stenting. Periprocedural complica-
tions were few (n=3) and there were no fatalities. Last 
follow-up was at a median of 7.8 months (range: 0.1 - 
69.0) post initial procedure. Nine cases proceeded to 
corrective surgery. Surgery was delayed by a median 
13.5 months (range: 0.3 - 69.0 months) and weight 
increased to a median of  10.3kg (p<0.001). Five cases 
demised at a median of 73 days (range: 1 - 422) post 
initial stent placement, most at home secondary to 
unknown causes. Four patients remain in follow-up. 
One patient was lost to follow-up.
Conclusion: The placement of stents in small, ill children 
is feasible. It immediately relieves the obstruction and 
improves the general clinical condition. Surgery can be 
delayed for weeks or months, thus giving the opportunity 


















Congenital aortic arch obstruction is common. Primary surgical 
repair is the treatment of choice in newborns with COA.(10) 
Primary surgical repair and redo surgeries in critically ill patients 
are risky and there is a higher rate of recoarctation (10% - 29%) 
in very small and premature infants. Also, COA associated with 
other lesions and complicated by left ventricular dysfunction 
and cardiorespiratory decompensation, may adversely affect 
surgical outcomes.(3,11) Percutaneous balloon angioplasty of 
native COA in infants is associated with suboptimal and 
unpredictable results and has a risk of restenosis and aneurysm 
formation, especially in patients with long segment or complex 
COA.(12-14) 
The use of stents is an accepted and well-established 
method of treating children with congenital heart disease. The 
reported periprocedural complications and mortality rates have 
been low.(14) Experience in stenting very young and small 
patients with critical obstructive congenital heart disease is 
limited and consists mostly of case reports and a few review 
articles.(5,6,10-12,15-31) The majority reported good immediate 
results, but limited data on follow-up and final outcomes is 
available. 
The aim of this study was to determine whether the use of 
small stents is feasible and if surgery could be delayed as well as 
to analyse the short and medium-term outcomes.
MATERIALS AND METHODS
This was a retrospective analysis done from August 2006 - 
December 2013 of patients presenting at our centre. The local 
Paediatric cardiology database as well as the hospital records 
were used to acquire the required data.
Inclusion criteria
Patients were included in circumstances where surgery needed 
to be delayed and the implantation of a small stent could 
alleviate the underlying obstruction. During this period 19 
patients were identified.
Technical aspects
All procedures were performed under general anesthesia. 
Vascular access was obtained via the femoral artery and/or vein 
depending on the procedure and the smallest possible sheath 
size was used (4-6 French). Routine intravenous antibiotics 
(2nd generation Cephalosporin) were given at commencement 
of the procedure and continued 8 hourly thereafter for a total 
of 3 doses. Intravenous heparin was administered at com-
mencement (50U/kg) as well as post-procedure for 24 hours. 
All patients were started on low dose (2 - 3mg/kg/day) oral 
acetylsalicylic acid post-procedure. As most patients were 
critically ill, limited diagnostic cardiac catheterisation and angio-
graphy was performed. Premounted, low profile, bare metal 
stents were preferred. 
Ethics and statistics
Approval by the local medical ethics committee was obtained. 
All cases involved a multidisciplinary team approach and the 
nature of the intervention was discussed prior to the procedure 
with the cardiothoracic surgeons. Written informed consent 
was obtained from parents or legal guardians, specifically for 
the use of the coronary stents off-label. The data was cap-
tured using Microsoft Excel spreadsheets and analysed using 
standard statistical software (PRISM v 4; GraphPad, San Diego, 
CA, US). The data is presented as medians with a range of 
minimum to maximum values where appropriate. Paired data 
was analysed using a student’s t-test. A p-value <0.05 was 
considered statistically significant.
RESULTS
Demographic and procedural data can be viewed in Tables I 
and 2. Median age at first stent placement was 4.6 months 
(range: 0.1 - 18.3 months) of which 35% required intervention 
within the first 2 months of life. Median weight was 4.5kg (range: 
1.7 - 9.5kg) with a quarter of patients weighing less than 2.5kg. 
There was a female preponderance with a ratio of almost 2:1 
(females n=12, males n=7). 
Patients had quite a diverse group of primary lesions, including 
both right and left sided obstructive lesions. The majority of 
patients had aortic arch obstruction (n=9). Almost half of the 
patients had undergone previous surgery. Obstructive lesions 
requiring stenting included native COA (n=5), post-operative 
recoarctation (n=4), native RVOT obstruction (n=3), systemic-
to-pulmonary artery shunt occlusion (n=5), native infradia-
phragmatic pulmonary vein obstruction (n=1) and also a 
markedly stenosed native patent ductus arteriosus (PDA) to a 
discontinuous left pulmonary artery (LPA) (n=1). Reasons 
patients were not fit for surgical intervention at that time, 
included very low weight <2.5kg (n=4), poor general clinical 
condition with associated anesthetic risk (n=12), potential 
technical difficulty of the procedure due to the nature of the 
lesion (n=2) and unavailability of a critical care bed (n=1). 
Procedure
Balloon angioplasty preceding stenting was required in 2 cases. 
In the majority (68%) of cases only one stent was necessary to 
treat the obstruction. Eighty percent of stents were 5mm or 
smaller in diameter.
Immediate outcome
All attempts at stenting were successful (100%). Angiographic 
examples of obstructive lesions can be viewed in Figures 1 to 4. 
The gradient over the COAs was significantly reduced: from 
a median 43.5mmHg - 12.7mmHg (n=6, p<0.001) and the 
narrowest diameter increased from a median 1.8mm (range: 1.3 
to 2.4mm) to 4.0mm (range: 3.3 - 5.8mm ) (n=7, p<0.001). 
Saturations improved in all patients with obstructive pulmonary 
blood flow to more than 85%.
Complications
There were no periprocedural deaths. Complications were few 
and easily managed. These included a temporary bradycardia 
that needed cardiac massage and atrial fibrillation requiring 
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electrical cardioversion. Technical difficulty in stent placement 
in one case led to stent dislodgement, which was successfully 
managed by fixation with additional stents.
Follow up
A summary of medium term outcomes can be viewed in 
Figure 5. Patients have been followed up for a median 7.8 
months (range: 0.1 - 69.0 months). Six patients required a 
second procedure (balloon angioplasty n=4, restent n=2) at 
a median 4.7 months (range: 1.6 - 17.8 months) post initial 
procedure to accommodate for growth, 5 having had a previous 
aortic arch stent. Nine patients were scheduled for elective 
corrective surgery at a median 7.8 months (range: 0.3 - 69.0 
months) after first stent implantation. During the follow-up 
period, two cases with coarctation were able to undergo repair 
of associated lesions (VSD closure). There were 5 deaths at a 
median of 73 days (range: 1 - 422 days) since the first stenting 
procedure was performed. Patient 5 was sent home for pallia-
tive care. He had an inoperable VSD due to accelerated 
development of severe pulmonary hypertension. Patient 16 
was a critically ill patient with severe hypoxia and acidosis after 
occlusion of a Blalock-Taussig shunt performed 8 days before 
at 25 days of age. Patients 2, 10 and 19 died at home of 
undetermined causes. Four patients currently remain in follow-
up and are doing well. Surgery has so far been postponed by a 
median 13.5 months (n=13, range: 0.3 - 69.0 months; patients 
that died and were lost to follow-up were excluded). In 10 of 
these patients, weight had also increased from a median 4.6kg 
to 10.3kg (p<0.001). One patient has been lost to follow up 
and was last seen at 1.4 months post first procedure doing well 
and was scheduled to follow up in 6 months.
DISCUSSION 
Results of our study show that the use of small stents to treat 
obstruction in young, critically ill children is feasible. Immediate 
success is good and periprocedural complications few. Surgery 
can be delayed short term until condition improves or longer 
(may need redilation) if required.
Most of our patients were small and 2 weighed less than 2kg. 
The procedure was technically relatively easy in most cases and 
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TABLE 1:  Demographic data. 
Age and weight at time of first stent procedure.
COA: coarctation of the aorta, IAA: interrupted aortic arch, DORV & PS: double outlet right ventricle and pulmonary stenosis, Tet: tetralogy of Fallot, PA: pulmonary atresia, d-TGA: dextro 
transposition of the great arteries, TA: tricuspid atresia, TAPVD: total anomalous pulmonary venous drainage, LPA: left pulmonary artery, PDA: patent ductus arteriosus, VSD: ventricular 
septal defect, ASD: atrial septal defect, MAPCAs: major aortopulmonary collateral arteries, BTS: Blalock-Tausig shunt, DKS: Damus-Kaye-Stansel.   
  Age Weight 
Primary lesion Associated lesions Stent procedure Indication for stent
 
  (months) (kg)
 1  1.5 3.9 COA PDA, VSD Native COA Critically ill - post PDA ligation 
       and cardiac failure
 2  2.67 3.17 COA PDA, VSD, ASD Recoarctation Surgical technical diffi culty
 3  10.07 5.1 COA PDA Recoarctation Critically ill
 4  4.63 4.7 COA PDA, VSD Recoarctation No intensive care bed available
 5  4.87 5.4 COA PDA, VSD Native COA Critically ill - very large VSD 
       and cardiac failure
 6  5.27 6.0 COA PDA Native COA Critically ill
 7  1.13 1.8 COA PDA, VSD Native COA Extremely low weight
 8  7.57 4.5 COA Bicuspid aortic valve Native COA Critically ill
 9  5.93 4.7 IAA Bicuspid aortic valve, VSD, ASD IAA arch repair stenosis Surgical technical diffi culty
10 1.93 2.4 DORV & PS PDA RVOT obstruction Very low weight
11 0.07 2.3 Tet  RVOT obstruction Very low weight
12 1.47 2.2 Tet PDA, MAPCAs RVOT obstruction Anaesthetic risk - airway 
       problem and very low weight
13 11.27 8.3 PA VSD, ASD, PDA, Ebstein Occluded shunt Critically ill
14 9.87 5.7 DORV & PS ASD Occluded shunt Critically ill
15 8.3 5.5 Tet  Occluded shunt Critically ill
16 1.1 3.8 d-TGA Aortic coarctation, ASD Occluded shunt Critically ill
17 17.67 9.5 TA PDA, MAPCAs Occluded shunt Critically ill
18 3.33 4.1 Subdiaphragmatic ASD Subdiaphragmatic pulmonary Critically ill - cardiac failure
    TAPVD  vein obstruction
19 0.43 1.67 Discontinuous  To maintain discontinuous Extremely low weight


















we were able to implant stents successfully in all patients, with 
immediate relief of all forms of obstruction. In 2 cases (patients 
15 and 18), balloon angioplasty prior to stent placement was 
required because of the severity of the stenosis, making it 
possible to safely advance the stent beyond the obstruction. 
TABLE 2:  Procedural data. 
Manufacturers: LiberteTM, Boston Scientific, Natick, MA; Genesis®, Cordis, Warren, NJ; Racer RX, Medtronic Inc., Minneapolis, MN; OmegaTM, Boston Scientific, Natick, MA; FormulaTM, 
Cook Inc., Bloomington, IN; Integrity®, Medtronic Inc., Minneapolis, MN. 
*patient 11: additional stents placed - LiberteTM 5mmx12mm (3rd) and 5mmx24mm (4th).
   FIRST STENT      SECOND STENT    
  Sheath Type Diameter (mm) Length (mm)  Type Diameter (mm) Length (mm)
  size (F)
 1  4 LiberteTM 5 12    
 2  4 LiberteTM 4 8    
 3  4 Genesis®  6 12    
 4  4 Genesis® 5.5 15    
 5  4 LiberteTM 5 16 LiberteTM 5 12
 6  4 Racer RX 6 12    
 7  4 OmegaTM 3.5 12 LiberteTM 3.5 16
 8  5 FormulaTM 6 16    
 9  4 LiberteTM 5 12    
10 4 LiberteTM 5 12    
11 5 Integrity® 4 15 LiberteTM 5 16*
12 5 LiberteTM 5 12    
13 5 LiberteTM 4 12    
14 4 LiberteTM 4.5 16    
15 4 LiberteTM 4.5 20 LiberteTM 4.5 12
16 4 OmegaTM 4 8 OmegaTM 4 8
17 5 OmegaTM 4 20    
18 6 Genesis® 8 12    
19 4 LiberteTM 2.5 12 LiberteTM 2.5 12
we were able to implant stents successfully in all patients, with 
immediate relief of all forms of obstruction. In 2 cases (patients 
15 and 18), balloon angioplasty prior to stent placement was 
required because of the severity of the stenosis, making it 
possible to safely advance the stent beyond the obstruction. 
FIGURE 1: Stenting of native COA (patient 1).
Lateral angiographic view. Arrow indicates area of COA in 
descending aorta (A).
Antero-posterior (AP) angiographic view. Arrow indicates 
successful COA stent with much improved flow to descending 
aorta (B).
FIGURE 2: Stenting of pos  surgical recoarctation of the 
aorta (patient 3).
AP angiographic view. Arrow indicates area of severe narrowing 
in aortic arch proximal to left subclavian artery in a patient post 
COA repair (A).
AP angiographic view. Arrow indicates area of stent placement in 






Almost half the patients had undergone prior surgery. Four 
patients had undergone aortic arch repair and 5 patients a 
systemic-to-pulmonary artery shunt procedure that subse-
quently required emergency management. Redo surgeries in 
these small, critically ill children would have been extremely 
challenging due to localisation of the obstruction or clinical 
condition at the time of presentation. Small stents under these 
circumstances may be a useful option to supplement future 
surgery. In our experience, stents should be used in a post 
surgical lesion where marked elastic recoil is observed after 
balloon angioplasty.
Stenting is considered safe and has been extended for use in 
the management of complex obstructive congenital heart 
disease in small newborns and infants over the last few years. 
Reported success rate ranges between 80% - 100%.(5, 6, 10-12, 15-31) 
Our findings compare favourably with this. Overall, low peri-
procedural complication rates have been reported in stents 
used in older children (up to 16%). These include stent migra-
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FIGURE 4: Stenting of PDA to discontinuous LPA 
(patient 19).
AP angiographic view. Arrow indicates PDA with severe stenosis 
at junction with discontinuous LPA (A).
AP angiographic view. Arrow indicates PDA stent with much 
improved blood flow to LPA (B).
A B
FIGURE 3: Stenting of subdiaphragmatic pulmonary 
venous obstruction (patient 18).
AP angiographic view. Arrow indicates area of severe obstruction 
below the diaphragm at the junction of the pulmonary vein to the 
IVC, crossed by a guide wire prestent placement (A). 
AP angiographic view. Arrow indicates area of stent placement 
showing improvement of flow in pulmonary venous chamber (B).
A B
FIGURE 5: Summary of medium term outcomes at 
follow up after initial stent placement.
Aortic arch obstruction group (A). 
BA, balloon angioplasty.
RVOT obstruction group (B). 
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tion (5%), stent malposition (3-16%) and vascular compro-
mise.(21,32,33) In younger and smaller patients, complications 
mostly consist of vascular compromise, haemorrhage and 
dysrhythmias. Later complications include intrastent prolifera-
tion, restenosis and occlusion (3-36%).(5,10,12,25,31)
There were no periprocedural deaths in the study group and 
complications were mild and few: dysrhythmias (n=2) and stent 
migration (n=1). The latter occurred in patient 11. The first 
stent did not adequately cover the entire narrow portion of the 
RVOT. A second stent was placed, however this stent did not 
hook firmly onto the first stent. A third stent was then required 
to bridge this gap and during placement the second stent 
dislodged back into the right ventricle. A much longer fourth 
stent was then required to successfully stabilise the entire 
RVOT. We did not experience any vascular problems in any of 
the patients. 
A second procedure can be performed if required to extend 
the lifespan of the stent. Five patients that had previous aortic 
arch stents underwent second percutaneous procedures. Four 
of the 5 required only balloon angioplasty to accommodate for 
somatic growth and further postpone surgery. These patients 
will be followed up closely for development of stent narrowing 
and referred for surgery once it is no longer possible to manage 
the patient percutaneously. One stent fractured on redilation. 
Implanting a larger covered stent successfully treated this. 
Almost 5 years later this patient still remains in follow-up and is 
doing well. We observed minimal stent peeling at this second 
procedure and we can only speculate that it may be related to 
the administration of aspirin or that peeling is less frequent if 
stent diameter exceeds a certain minimum (the majority of our 
stents were expanded to 5mm).
Surgery could be delayed and clinical condition improved in all 
patients. Two patients were also able to undergo elective 
surgical VSD closure after COA stenting at a time when they 
were clinically stable, out of cardiac failure and had gained 
significant weight. Elective repair of native COA was carried 
out in patient one, 2 weeks after stent implantation after cardiac 
failure abated. In patient 3, redo COA repair was delayed by 
more than 5 years and in patient 7 (that was 1.8kg at stent 
procedure), COA repair was delayed by 18 months. There was 
also a statistically significant increase in weight in patients that 
proceeded to corrective surgery and in those that remain in 
follow-up. The 4 patients that currently remain in follow-up all 
had COA stents. They are doing well without medication and 
have minimal COA gradients. Future surgery may be necessary 
once somatic growth overcomes the ability to further balloon 
dilate the stent.
The overall mortality rate in our study was 26%, which is similar 
to other reports in these small, critically ill children and com-
pares favourably to overall surgical mortality. However, as the 
group of patients is quite diverse, it is difficult to compare 
the overall mortality to a similar surgical series.(3-6,10-12,15-31) 
Mortality in surgical COA repairs in infants for example, is 
known to be much lower (<2%), but higher in small, complex 
patients (5 - 25%).(3,12) It should be mentioned that one patient 
was sent home for palliative care and one patient had severe 
post-operative hypoxia and acidosis. The deaths at home raise 
concern, as it is unknown whether they were attributed to 
the stents or not. In our setting, follow-up can be proble-
matic. Patients face challenges such as transport, financial 
problems and migrant labour, which make it difficult to attend 
regular scheduled follow-up visits. Patients become lost in 
the system and only reappear once critically ill. One patient 
defaulted follow-up for 4 years post RVOT stent and presented 
with near total stent occlusion. She subsequently proceeded 
to surgical repair.
Advantages of placing stents at a young age include the 
abolishment of severe obstruction, avoidance of major cardiac 
surgery during a time of critical illness and potentially shorter 
hospital stays. Disadvantages of early stenting in small patients 
consist of: vascular compromise and an increased rate of 
developing instent stenosis due to the use of smaller diameter 
stents (the incidence of abrupt stent thrombosis is un-
certain).(25,32) However, the purpose of implanting stents in this 
subgroup of patients is not to avoid, but only to delay surgery 
until either clinical condition improves (days) or somatic growth 
allows lower risk surgery (weeks to months). We consider the 
team approach and joint decision-making process with our 
surgeons not only extremely helpful and beneficial, but essential.
STUDY LIMITATIONS
The small number of patients and its retrospective nature limits 
this study, but emphasises that this procedure only applies to a 
select subgroup of patients. Certain procedural information 
such as paired pre and post procedure pressure gradients, 
diameters and saturation values could not be obtained in all 
patients, as most were critically ill and time was of the essence. 
We were also not able to ascertain the cause of death in 4 of 
the children who died at home.
CONCLUSION
The placement of small stents for these obstructive lesions 
(either native or post surgical) in small, ill children is feasible and 
associated with minimal complications. It immediately relieves 
the obstruction and improves the general clinical condition. It 
allows surgery to be delayed from days to months, giving 
opportunity for somatic growth. Mortality remains high in this 
group of high-risk critically ill patients. There are unique chal-
lenges in our setting and therefore short interval follow-up is 
crucial to monitor these patients closely and prevent defaulting. 
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